Cisco Stock Forecast: Is It Ready to Surprise Us?
Let’s be real Cisco Systems (NASDAQ: CSCO) hasn’t exactly been…
Sell
26
EDIT Quote, Financials, Valuation and Earnings
Last price:
$1.55
Seasonality move
:
7.79%
Day range:
$1.51 - $1.59
52-week range:
$0.91 - $6.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.57x
P/B ratio:
2.08x
Volume:
952.7K
Avg. volume:
1.8M
1-year change:
-73.41%
Market cap:
$129.8M
Revenue:
$32.3M
EPS (TTM):
-$3.04
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EDIT
Editas Medicine
|
$1.8M | -$0.33 | 251.82% | -54.6% | $3.38 |
|
ABUS
Arbutus Biopharma
|
$1.6M | -$0.06 | -7.67% | -40.73% | $5.25 |
|
AVXL
Anavex Life Sciences
|
-- | -$0.15 | -- | -3.57% | $34.33 |
|
EYPT
EyePoint Pharmaceuticals
|
$7.8M | -$0.77 | -34.92% | -41.97% | $32.00 |
|
OCGN
Ocugen
|
$300K | -$0.06 | -69.33% | -41.68% | $6.50 |
|
TGTX
TG Therapeutics
|
$153.1M | $0.27 | 101.13% | 653.48% | $41.20 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EDIT
Editas Medicine
|
$1.55 | $3.38 | $129.8M | -- | $0.00 | 0% | 3.57x |
|
ABUS
Arbutus Biopharma
|
$3.22 | $5.25 | $616.7M | -- | $0.00 | 0% | 95.23x |
|
AVXL
Anavex Life Sciences
|
$7.53 | $34.33 | $642.9M | -- | $0.00 | 0% | -- |
|
EYPT
EyePoint Pharmaceuticals
|
$5.68 | $32.00 | $390.9M | -- | $0.00 | 0% | 6.13x |
|
OCGN
Ocugen
|
$0.93 | $6.50 | $271.8M | -- | $0.00 | 0% | 57.56x |
|
TGTX
TG Therapeutics
|
$34.57 | $41.20 | $5.5B | 144.04x | $0.00 | 0% | 14.39x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EDIT
Editas Medicine
|
-- | 0.641 | -- | 3.03x |
|
ABUS
Arbutus Biopharma
|
-- | 0.274 | -- | 5.86x |
|
AVXL
Anavex Life Sciences
|
-- | 0.928 | -- | -- |
|
EYPT
EyePoint Pharmaceuticals
|
-- | -2.418 | -- | 7.65x |
|
OCGN
Ocugen
|
63.49% | 0.941 | 13.41% | 2.24x |
|
TGTX
TG Therapeutics
|
-- | 1.159 | -- | 2.01x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EDIT
Editas Medicine
|
-- | -$35.3M | -139.77% | -139.77% | -1585.92% | -$47.9M |
|
ABUS
Arbutus Biopharma
|
-- | -$13M | -73.56% | -73.56% | -1388.78% | -$13.4M |
|
AVXL
Anavex Life Sciences
|
-- | -$12.4M | -- | -- | -- | -$5.9M |
|
EYPT
EyePoint Pharmaceuticals
|
$23.6M | -$48.8M | -55.1% | -55.1% | -199.72% | -$53.4M |
|
OCGN
Ocugen
|
-- | -$14.5M | -144.95% | -215.5% | -979.14% | -$19.4M |
|
TGTX
TG Therapeutics
|
$105.3M | $8.6M | 11.64% | 19.78% | 10.12% | -$28.7M |
Editas Medicine vs. Competitors
-
Which has Higher Returns EDIT or ABUS?
Arbutus Biopharma has a net margin of -1633.49% compared to Editas Medicine's net margin of -1390.36%. Editas Medicine's return on equity of -139.77% beat Arbutus Biopharma's return on equity of -73.56%.
Company Gross Margin Earnings Per Share Invested Capital EDITEditas Medicine-- -$0.92 $62.4M ABUSArbutus Biopharma-- -$0.13 $79.2M -
What do Analysts Say About EDIT or ABUS?
Editas Medicine has a consensus price target of $3.38, signalling upside risk potential of 117.74%. On the other hand Arbutus Biopharma has an analysts' consensus of $5.25 which suggests that it could grow by 62.99%. Given that Editas Medicine has higher upside potential than Arbutus Biopharma, analysts believe Editas Medicine is more attractive than Arbutus Biopharma.
Company Buy Ratings Hold Ratings Sell Ratings EDITEditas Medicine4 8 0 ABUSArbutus Biopharma2 1 0 -
Is EDIT or ABUS More Risky?
Editas Medicine has a beta of 2.149, which suggesting that the stock is 114.892% more volatile than S&P 500. In comparison Arbutus Biopharma has a beta of 1.502, suggesting its more volatile than the S&P 500 by 50.242%.
-
Which is a Better Dividend Stock EDIT or ABUS?
Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arbutus Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. Arbutus Biopharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDIT or ABUS?
Editas Medicine quarterly revenues are $4.7M, which are larger than Arbutus Biopharma quarterly revenues of $1.8M. Editas Medicine's net income of -$76.1M is lower than Arbutus Biopharma's net income of -$24.5M. Notably, Editas Medicine's price-to-earnings ratio is -- while Arbutus Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 3.57x versus 95.23x for Arbutus Biopharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDITEditas Medicine3.57x -- $4.7M -$76.1M ABUSArbutus Biopharma95.23x -- $1.8M -$24.5M
-
Which has Higher Returns EDIT or AVXL?
Anavex Life Sciences has a net margin of -1633.49% compared to Editas Medicine's net margin of --. Editas Medicine's return on equity of -139.77% beat Anavex Life Sciences's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital EDITEditas Medicine-- -$0.92 $62.4M AVXLAnavex Life Sciences-- -$0.13 -- -
What do Analysts Say About EDIT or AVXL?
Editas Medicine has a consensus price target of $3.38, signalling upside risk potential of 117.74%. On the other hand Anavex Life Sciences has an analysts' consensus of $34.33 which suggests that it could grow by 355.95%. Given that Anavex Life Sciences has higher upside potential than Editas Medicine, analysts believe Anavex Life Sciences is more attractive than Editas Medicine.
Company Buy Ratings Hold Ratings Sell Ratings EDITEditas Medicine4 8 0 AVXLAnavex Life Sciences2 0 0 -
Is EDIT or AVXL More Risky?
Editas Medicine has a beta of 2.149, which suggesting that the stock is 114.892% more volatile than S&P 500. In comparison Anavex Life Sciences has a beta of 0.820, suggesting its less volatile than the S&P 500 by 18.046%.
-
Which is a Better Dividend Stock EDIT or AVXL?
Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anavex Life Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. Anavex Life Sciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDIT or AVXL?
Editas Medicine quarterly revenues are $4.7M, which are larger than Anavex Life Sciences quarterly revenues of --. Editas Medicine's net income of -$76.1M is lower than Anavex Life Sciences's net income of -$11.2M. Notably, Editas Medicine's price-to-earnings ratio is -- while Anavex Life Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 3.57x versus -- for Anavex Life Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDITEditas Medicine3.57x -- $4.7M -$76.1M AVXLAnavex Life Sciences-- -- -- -$11.2M
-
Which has Higher Returns EDIT or EYPT?
EyePoint Pharmaceuticals has a net margin of -1633.49% compared to Editas Medicine's net margin of -184.82%. Editas Medicine's return on equity of -139.77% beat EyePoint Pharmaceuticals's return on equity of -55.1%.
Company Gross Margin Earnings Per Share Invested Capital EDITEditas Medicine-- -$0.92 $62.4M EYPTEyePoint Pharmaceuticals96.71% -$0.65 $298.4M -
What do Analysts Say About EDIT or EYPT?
Editas Medicine has a consensus price target of $3.38, signalling upside risk potential of 117.74%. On the other hand EyePoint Pharmaceuticals has an analysts' consensus of $32.00 which suggests that it could grow by 463.38%. Given that EyePoint Pharmaceuticals has higher upside potential than Editas Medicine, analysts believe EyePoint Pharmaceuticals is more attractive than Editas Medicine.
Company Buy Ratings Hold Ratings Sell Ratings EDITEditas Medicine4 8 0 EYPTEyePoint Pharmaceuticals9 0 0 -
Is EDIT or EYPT More Risky?
Editas Medicine has a beta of 2.149, which suggesting that the stock is 114.892% more volatile than S&P 500. In comparison EyePoint Pharmaceuticals has a beta of 1.581, suggesting its more volatile than the S&P 500 by 58.087%.
-
Which is a Better Dividend Stock EDIT or EYPT?
Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. EyePoint Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDIT or EYPT?
Editas Medicine quarterly revenues are $4.7M, which are smaller than EyePoint Pharmaceuticals quarterly revenues of $24.5M. Editas Medicine's net income of -$76.1M is lower than EyePoint Pharmaceuticals's net income of -$45.2M. Notably, Editas Medicine's price-to-earnings ratio is -- while EyePoint Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 3.57x versus 6.13x for EyePoint Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDITEditas Medicine3.57x -- $4.7M -$76.1M EYPTEyePoint Pharmaceuticals6.13x -- $24.5M -$45.2M
-
Which has Higher Returns EDIT or OCGN?
Ocugen has a net margin of -1633.49% compared to Editas Medicine's net margin of -1036.46%. Editas Medicine's return on equity of -139.77% beat Ocugen's return on equity of -215.5%.
Company Gross Margin Earnings Per Share Invested Capital EDITEditas Medicine-- -$0.92 $62.4M OCGNOcugen-- -$0.05 $43.6M -
What do Analysts Say About EDIT or OCGN?
Editas Medicine has a consensus price target of $3.38, signalling upside risk potential of 117.74%. On the other hand Ocugen has an analysts' consensus of $6.50 which suggests that it could grow by 598.32%. Given that Ocugen has higher upside potential than Editas Medicine, analysts believe Ocugen is more attractive than Editas Medicine.
Company Buy Ratings Hold Ratings Sell Ratings EDITEditas Medicine4 8 0 OCGNOcugen2 0 0 -
Is EDIT or OCGN More Risky?
Editas Medicine has a beta of 2.149, which suggesting that the stock is 114.892% more volatile than S&P 500. In comparison Ocugen has a beta of 4.214, suggesting its more volatile than the S&P 500 by 321.428%.
-
Which is a Better Dividend Stock EDIT or OCGN?
Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDIT or OCGN?
Editas Medicine quarterly revenues are $4.7M, which are larger than Ocugen quarterly revenues of $1.5M. Editas Medicine's net income of -$76.1M is lower than Ocugen's net income of -$15.4M. Notably, Editas Medicine's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 3.57x versus 57.56x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDITEditas Medicine3.57x -- $4.7M -$76.1M OCGNOcugen57.56x -- $1.5M -$15.4M
-
Which has Higher Returns EDIT or TGTX?
TG Therapeutics has a net margin of -1633.49% compared to Editas Medicine's net margin of 4.19%. Editas Medicine's return on equity of -139.77% beat TG Therapeutics's return on equity of 19.78%.
Company Gross Margin Earnings Per Share Invested Capital EDITEditas Medicine-- -$0.92 $62.4M TGTXTG Therapeutics87.14% $0.03 $237.3M -
What do Analysts Say About EDIT or TGTX?
Editas Medicine has a consensus price target of $3.38, signalling upside risk potential of 117.74%. On the other hand TG Therapeutics has an analysts' consensus of $41.20 which suggests that it could grow by 19.18%. Given that Editas Medicine has higher upside potential than TG Therapeutics, analysts believe Editas Medicine is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings EDITEditas Medicine4 8 0 TGTXTG Therapeutics5 0 0 -
Is EDIT or TGTX More Risky?
Editas Medicine has a beta of 2.149, which suggesting that the stock is 114.892% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.208, suggesting its more volatile than the S&P 500 by 120.838%.
-
Which is a Better Dividend Stock EDIT or TGTX?
Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDIT or TGTX?
Editas Medicine quarterly revenues are $4.7M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Editas Medicine's net income of -$76.1M is lower than TG Therapeutics's net income of $5.1M. Notably, Editas Medicine's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 144.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 3.57x versus 14.39x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDITEditas Medicine3.57x -- $4.7M -$76.1M TGTXTG Therapeutics14.39x 144.04x $120.9M $5.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Gartner Stock Be in 5 Years?
If you’ve ever wondered what it’s like to invest in…
Rambus (RMBS) Stock Forecast, Can the Rally Continue in 2025?
Rambus has flown under the radar, but the numbers tell…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 45x
Sell
33
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Buy
60
MRUS alert for May 24
Merus NV [MRUS] is up 32.55% over the past day.
Buy
57
RGC alert for May 24
Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.
Buy
90
OKLO alert for May 24
Oklo [OKLO] is up 23.11% over the past day.
